In:
Journal of Cellular and Molecular Medicine, Wiley, Vol. 13, No. 4 ( 2009-04), p. 664-679
Abstract:
Erythropoietin (EPO) protects the myocardium from ischaemic injury and promotes beneficial remodelling. We assessed the therapeutic efficacy of intracardiac EPO injection and EPO‐mediated stem cell homing in a rat myocardial infarction (MI) model. Following MI, EPO (3000 U/kg) or saline was delivered by intracardiac injection. Compared to myocardial infarction control group (MIC), EPO significantly improved left ventricular function ( n = 11–14, P 〈 0.05) and decreased right ventricular wall stress ( n = 8, P 〈 0.05) assessed by pressure‐volume loops after 6 weeks. MI‐EPO hearts exhibited smaller infarction size (20.1 ± 1.1% versus 27.8 ± 1.2%; n = 6–8, P 〈 0.001) and greater capillary density (338.5 ± 14.7 versus 259.8 ± 9.2 vessels per mm; n = 6–8, P 〈 0.001) than MIC hearts. Direct EPO injection reduced post‐MI myocardial apoptosis by approximately 41% (0.27 ± 0.03% versus 0.42 ± 0.03%; n = 6, P = 0.005). The chemoattractant SDF‐1 was up‐regulated significantly assessed by quantitative realtime PCR and immunohistology. c‐Kit + and CD34 + stem cells were significantly more numerous in MI‐EPO than in MIC at 24 hrs in peripheral blood ( n = 7, P 〈 0.05) and 48 hrs in the infarcted hearts ( n = 6, P 〈 0.001). Further, the mRNAs of Akt, eNOS and EPO receptor were significantly enhanced in MI‐EPO hearts ( n = 7, P 〈 0.05). Intracardiac EPO injection restores myocardial functions following MI, which may attribute to the improved early recruitment of c‐Kit + and CD34 + stem cells via the enhanced expression of chemoattractant SDF‐1.
Type of Medium:
Online Resource
ISSN:
1582-1838
,
1582-4934
DOI:
10.1111/jcmm.2009.13.issue-4
DOI:
10.1111/j.1582-4934.2008.00546.x
Language:
English
Publisher:
Wiley
Publication Date:
2009
detail.hit.zdb_id:
2076114-4
Permalink